1195 related articles for article (PubMed ID: 10430831)
1. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
2. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease.
Piggott MA; Perry EK; Marshall EF; McKeith IG; Johnson M; Melrose HL; Court JA; Lloyd S; Fairbairn A; Brown A; Thompson P; Perry RH
Biol Psychiatry; 1998 Oct; 44(8):765-74. PubMed ID: 9798081
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Costa D; Perry RH; Perry EK
Neuroscience; 1999 May; 90(2):433-45. PubMed ID: 10215149
[TBL] [Abstract][Full Text] [Related]
4. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
[TBL] [Abstract][Full Text] [Related]
5. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication.
Court JA; Piggott MA; Lloyd S; Cookson N; Ballard CG; McKeith IG; Perry RH; Perry EK
Neuroscience; 2000; 98(1):79-87. PubMed ID: 10858614
[TBL] [Abstract][Full Text] [Related]
6. Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia.
Piggott MA; Ballard CG; Dickinson HO; McKeith IG; Perry RH; Perry EK
Int J Neuropsychopharmacol; 2007 Apr; 10(2):231-44. PubMed ID: 16448581
[TBL] [Abstract][Full Text] [Related]
7. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
[TBL] [Abstract][Full Text] [Related]
8. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use.
Court JA; Lloyd S; Thomas N; Piggott MA; Marshall EF; Morris CM; Lamb H; Perry RH; Johnson M; Perry EK
Neuroscience; 1998 Nov; 87(1):63-78. PubMed ID: 9722142
[TBL] [Abstract][Full Text] [Related]
9. Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.
Walker Z; Costa DC; Janssen AG; Walker RW; Livingstone G; Katona CL
Eur J Nucl Med; 1997 Jun; 24(6):609-14. PubMed ID: 9169566
[TBL] [Abstract][Full Text] [Related]
10. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis.
Sweet RA; Hamilton RL; Healy MT; Wisniewski SR; Henteleff R; Pollock BG; Lewis DA; DeKosky ST
Arch Neurol; 2001 Mar; 58(3):466-72. PubMed ID: 11255451
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease.
Piggott MA; Owens J; O'Brien J; Colloby S; Fenwick J; Wyper D; Jaros E; Johnson M; Perry RH; Perry EK
J Chem Neuroanat; 2003 Mar; 25(3):161-73. PubMed ID: 12706204
[TBL] [Abstract][Full Text] [Related]
12. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
Turjanski N; Lees AJ; Brooks DJ
Neurology; 1997 Sep; 49(3):717-23. PubMed ID: 9305330
[TBL] [Abstract][Full Text] [Related]
13. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors.
Joyce JN; Ryoo HL; Beach TB; Caviness JN; Stacy M; Gurevich EV; Reiser M; Adler CH
Brain Res; 2002 Nov; 955(1-2):138-52. PubMed ID: 12419530
[TBL] [Abstract][Full Text] [Related]
14. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.
Joyce JN; Murray AM; Hurtig HI; Gottlieb GL; Trojanowski JQ
Neuropsychopharmacology; 1998 Dec; 19(6):472-80. PubMed ID: 9803423
[TBL] [Abstract][Full Text] [Related]
15. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease.
Griffiths PD; Perry RH; Crossman AR
Neurosci Lett; 1994 Mar; 169(1-2):68-72. PubMed ID: 8047295
[TBL] [Abstract][Full Text] [Related]
16. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
Ułas J; Weihmuller FB; Brunner LC; Joyce JN; Marshall JF; Cotman CW
J Neurosci; 1994 Nov; 14(11 Pt 1):6317-24. PubMed ID: 7965038
[TBL] [Abstract][Full Text] [Related]
17. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
Chinaglia G; Alvarez FJ; Probst A; Palacios JM
Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
Ryoo HL; Pierrotti D; Joyce JN
Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
[TBL] [Abstract][Full Text] [Related]
19. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
20. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
